Roche CEO urges authorities to block Novo Nordisk's shareholder from acquiring Catalent, warning of potential harm to industry competitors. Concerns raised about impact on smaller players and limited availability of contract manufacturers. Roche unaffected due to reserved capacity with other manufacturers.